nach oben

18.05.2024 | Review

Early detection of pancreatic cancer in the era of precision medicine

verfasst von: Taha M. Ahmed, Satomi Kawamoto, Felipe Lopez-Ramirez, Mohammad Yasrab, Ralph H. Hruban, Elliot K. Fishman, Linda C. Chu

Erschienen in: Abdominal Radiology

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality and it is often diagnosed at advanced stages due to non-specific clinical presentation. Disease detection at localized disease stage followed by surgical resection remains the only potentially curative treatment. In this era of precision medicine, a multifaceted approach to early detection of PDAC includes targeted screening in high-risk populations, serum biomarkers and “liquid biopsies”, and artificial intelligence augmented tumor detection from radiologic examinations. In this review, we will review these emerging techniques in the early detection of PDAC.

Graphical abstract

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820.

Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Network Open. 2021;4(4):e214708. doi: https://doi.org/10.1001/jamanetworkopen.2021.4708.CrossRefPubMedPubMedCentral

Cancer of the Pancreas - Cancer Stat Facts. SEER. https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed September 30, 2023.

Hackert T, Klaiber U, Pausch T, Mihaljevic AL, Büchler MW. Fifty Years of Surgery for Pancreatic Cancer. Pancreas. 2020;49(8):1005–1013. doi: https://doi.org/10.1097/MPA.0000000000001634.CrossRefPubMed

Takikawa T, Kikuta K, Hamada S, et al. Clinical features and prognostic impact of asymptomatic pancreatic cancer. Sci Rep. 2022;12:4262. doi: https://doi.org/10.1038/s41598-022-08083-6.CrossRefPubMedPubMedCentral

Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg. 1986;203(1):77–81. doi: https://doi.org/10.1097/00000658-198601000-00013.CrossRefPubMedPubMedCentral

Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7–17. doi: https://doi.org/10.1136/gutjnl-2019-319352.CrossRefPubMed

Poruk KE, Firpo MA, Mulvihill SJ. Screening for pancreatic cancer. Adv Surg. 2014;48:115–136. doi: https://doi.org/10.1016/j.yasu.2014.05.004.CrossRefPubMed

Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg. 2012;16(4):771–783. doi: https://doi.org/10.1007/s11605-011-1781-6.CrossRefPubMed

10.

Del Chiaro M, Segersvärd R, Lohr M, Verbeke C. Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol. 2014;20(34):12118–12131. doi: https://doi.org/10.3748/wjg.v20.i34.12118.CrossRefPubMedPubMedCentral

11.

Nagata N, Kawazoe A, Mishima S, et al. Development of Pancreatic Cancer, Disease-specific Mortality, and All-Cause Mortality in Patients with Nonresected IPMNs: A Long-term Cohort Study. Radiology. 2016;278(1):125–134. doi: https://doi.org/10.1148/radiol.2015150131.CrossRefPubMed

12.

Hruban RH, Maitra A, Goggins M. Update on Pancreatic Intraepithelial Neoplasia. Int J Clin Exp Pathol. 2008;1(4):306–316.PubMedPubMedCentral

13.

Gangi S, Fletcher JG, Nathan MA, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol. 2004;182(4):897–903. doi: https://doi.org/10.2214/ajr.182.4.1820897.CrossRefPubMed

14.

Toshima F, Watanabe R, Inoue D, et al. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study. American Journal of Roentgenology. American Roentgen Ray Society; 2021;217(6):1353–1364. doi: https://doi.org/10.2214/AJR.21.26014.CrossRefPubMed

15.

Park BK, Koh HD, Won SY, et al. Suspicious findings observed retrospectively on CT imaging performed before the diagnosis of pancreatic cancer. J Gastrointest Oncol. 2023;14(2):1008–1018. doi: https://doi.org/10.21037/jgo-22-863.CrossRefPubMedPubMedCentral

16.

Singh DP, Sheedy S, Goenka AH, et al. Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospective study. Pancreatology. 2020;20(7):1495–1501. doi: https://doi.org/10.1016/j.pan.2020.07.410.CrossRefPubMed

17.

Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64(11):1783–1789. doi: https://doi.org/10.1136/gutjnl-2014-308653.CrossRefPubMed

18.

Nakahodo J, Kikuyama M, Fukumura Y, et al. Focal pancreatic parenchyma atrophy is a harbinger of pancreatic cancer and a clue to the intraductal spreading subtype. Pancreatology. 2022;22(8):1148–1158. doi: https://doi.org/10.1016/j.pan.2022.10.003.CrossRefPubMed

19.

Henrikson NB, Aiello Bowles EJ, Blasi PR, et al. Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019;322(5):445–454. doi: https://doi.org/10.1001/jama.2019.6190.CrossRefPubMed

20.

Ibrahim IS, Bonsing BA, Swijnenburg R-J, et al. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. Familial Cancer. 2017;16(1):111–115. doi: https://doi.org/10.1007/s10689-016-9915-3.CrossRefPubMed

21.

Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009;133(3):365–374. doi: https://doi.org/10.5858/133.3.365.CrossRefPubMedPubMedCentral

22.

Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer. 2009;8(2):109–117. doi: https://doi.org/10.1007/s10689-008-9214-8.CrossRefPubMed

23.

Harinck F, Konings IC a. W, Kluijt I, et al. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut. BMJ Publishing Group; 2016;65(9):1505–1513. doi: https://doi.org/10.1136/gutjnl-2014-308008.CrossRefPubMed

24.

Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020;159(1):358–362. doi: https://doi.org/10.1053/j.gastro.2020.03.088.CrossRefPubMed

25.

Freeny PC, Marks WM, Ryan JA, Traverso LW. Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. Radiology. Radiological Society of North America; 1988;166(1):125–133. doi: https://doi.org/10.1148/radiology.166.1.2827228.CrossRefPubMed

26.

Frampas E, Morla O, Regenet N, Eugène T, Dupas B, Meurette G. A solid pancreatic mass: Tumour or inflammation? Diagnostic and Interventional Imaging. 2013;94(7):741–755. doi: https://doi.org/10.1016/j.diii.2013.03.013.CrossRefPubMed

27.

Huang C, Simeone DM, Luk L, et al. Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consortium. American Journal of Roentgenology. American Roentgen Ray Society; 2022;219(6):903–914. doi: https://doi.org/10.2214/AJR.22.27859.CrossRefPubMed

28.

Kang KM, Lee JM, Shin C-I, et al. Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas. J Magn Reson Imaging. 2013;38(3):555–563. doi: https://doi.org/10.1002/jmri.24022.CrossRefPubMed

29.

Fatima Z, Ichikawa T, Motosugi U, et al. Magnetic resonance diffusion-weighted imaging in the characterization of pancreatic mucinous cystic lesions. Clin Radiol. 2011;66(2):108–111. doi: https://doi.org/10.1016/j.crad.2010.10.004.CrossRefPubMed

30.

Dbouk M, Katona BW, Brand RE, et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. JCO. Wolters Kluwer; 2022;40(28):3257–3266. https://doi.org/10.1200/JCO.22.00298.

31.

Canto MI, Almario JA, Schulick RD, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology. 2018;155(3):740-751.e2. doi: https://doi.org/10.1053/j.gastro.2018.05.035.CrossRefPubMed

32.

Paiella S, Salvia R, De Pastena M, et al. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Pancreatology. 2018;18(4):420–428. doi: https://doi.org/10.1016/j.pan.2018.04.002.CrossRefPubMed

33.

Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–719. doi: https://doi.org/10.4161/rna.20481.CrossRefPubMedPubMedCentral

34.

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi: https://doi.org/10.1126/science.1235122.CrossRefPubMedPubMedCentral

35.

Macgregor-Das A, Yu J, Tamura K, et al. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. The Journal of Molecular Diagnostics. 2020;22(6):748–756. doi: https://doi.org/10.1016/j.jmoldx.2020.02.010.CrossRefPubMedPubMedCentral

36.

Bettegowda C, Sausen M, Leary RJ, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine. American Association for the Advancement of Science; 2014;6(224):224ra24–224ra24. https://doi.org/10.1126/scitranslmed.3007094.

37.

Cohen JD, Javed AA, Thoburn C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2017;114(38):10202–10207. doi: https://doi.org/10.1073/pnas.1704961114.CrossRef

38.

Sefrioui D, Blanchard F, Toure E, et al. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017;117(7):1017–1025. doi: https://doi.org/10.1038/bjc.2017.250.CrossRefPubMedPubMedCentral

39.

Zhu Y, Zhang H, Chen N, Hao J, Jin H, Ma X. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. Medicine. 2020;99(3):e18581. doi: https://doi.org/10.1097/MD.0000000000018581.CrossRefPubMedPubMedCentral

40.

Gorgannezhad L, Umer M, Islam MN, Nguyen N-T, Shiddiky MJA. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab Chip. 2018;18(8):1174–1196. doi: https://doi.org/10.1039/C8LC00100F.CrossRefPubMed

41.

Martin-Alonso C, Tabrizi S, Xiong K, et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science. 2024;383(6680):eadf2341. https://doi.org/10.1126/science.adf2341.

42.

Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol. 2013;10(6):327–335. doi: https://doi.org/10.1038/nrurol.2013.89.CrossRefPubMed

43.

Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based biomarkers in colorectal cancer: A systematic review. Biochim Biophys Acta. 2016;1866(1):106–120. doi: https://doi.org/10.1016/j.bbcan.2016.07.001.CrossRefPubMed

44.

Ying L, Sharma A, Chhoda A, et al. Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer. Pancreas. 2021;50(9):1267. doi: https://doi.org/10.1097/MPA.0000000000001919.CrossRefPubMed

45.

Eissa MAL, Lerner L, Abdelfatah E, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenetics. 2019;11(1):59. doi: https://doi.org/10.1186/s13148-019-0650-0.CrossRefPubMedPubMedCentral

46.

Introducing the Avantect Pancreatic Cancer Test. Avantect. https://www.avantect.com/. Accessed March 28, 2024.

47.

Galleri Test. GRAIL. https://grail.com/galleri-test/. Accessed March 28, 2024.

48.

Mazer BL, Lee JW, Roberts NJ, et al. Screening for pancreatic cancer has the potential to save lives, but is it practical? Expert Rev Gastroenterol Hepatol. 2023;17(6):555–574. doi: https://doi.org/10.1080/17474124.2023.2217354.CrossRefPubMed

49.

Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann B. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers. Multidisciplinary Digital Publishing Institute; 2019;11(11):1659. doi: https://doi.org/10.3390/cancers11111659.CrossRefPubMedPubMedCentral

50.

Kulemann B, Pitman MB, Liss AS, et al. Circulating Tumor Cells Found in Patients With Localized and Advanced Pancreatic Cancer. Pancreas. 2015;44(4):547. doi: https://doi.org/10.1097/MPA.0000000000000324.CrossRefPubMed

51.

Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–361. doi: https://doi.org/10.1016/j.cell.2011.11.025.CrossRefPubMedPubMedCentral

52.

Lozar T, Gersak K, Cemazar M, Kuhar CG, Jesenko T. The Biology and Clinical Potential of Circulating Tumor Cells. Radiol Oncol. 2019;53(2):131–147. doi: https://doi.org/10.2478/raon-2019-0024.CrossRefPubMedPubMedCentral

53.

Wei T, Zhang X, Zhang Q, et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Letters. 2019;452:237–243. doi: https://doi.org/10.1016/j.canlet.2019.03.009.CrossRefPubMed

54.

Chen J, Wang H, Zhou L, Liu Z, Tan X. A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer. J Clin Lab Anal. 2022;36(5):e24341. doi: https://doi.org/10.1002/jcla.24341.CrossRefPubMedPubMedCentral

55.

Yeo D, Bastian A, Strauss H, Saxena P, Grimison P, Rasko JEJ. Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. Int J Mol Sci. 2022;23(3):1671. doi: https://doi.org/10.3390/ijms23031671.CrossRefPubMedPubMedCentral

56.

Ju S, Chen C, Zhang J, et al. Detection of circulating tumor cells: opportunities and challenges. Biomark Res. 2022;10:58. doi: https://doi.org/10.1186/s40364-022-00403-2.CrossRefPubMedPubMedCentral

57.

Ko SW, Yoon SB. Clinical implications and perspectives of portal venous circulating tumor cells in pancreatic cancer. World J Gastrointest Oncol. 2023;15(4):632–643. doi: https://doi.org/10.4251/wjgo.v15.i4.632.CrossRefPubMedPubMedCentral

58.

Catenacci DVT, Chapman CG, Xu P, et al. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology. 2015;149(7):1794-1803.e4. doi: https://doi.org/10.1053/j.gastro.2015.08.050.CrossRefPubMed

59.

Junqueira-Neto S, Batista IA, Costa JL, Melo SA. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. Acta Cytol. 2019;63(6):479–488. doi: https://doi.org/10.1159/000493969.CrossRefPubMed

60.

Yadav DK, Bai X, Yadav RK, et al. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget. 2018;9(42):26900–26933. doi: https://doi.org/10.18632/oncotarget.24809.CrossRefPubMedPubMedCentral

61.

Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. Nature Publishing Group; 2015;523(7559):177–182. doi: https://doi.org/10.1038/nature14581.CrossRefPubMedPubMedCentral

62.

Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett. 2017;393:86–93. doi: https://doi.org/10.1016/j.canlet.2017.02.019.CrossRefPubMedPubMedCentral

63.

Madhavan B, Yue S, Galli U, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015;136(11):2616–2627. doi: https://doi.org/10.1002/ijc.29324.CrossRefPubMed

64.

Xiao D, Dong Z, Zhen L, et al. Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer. Molecular Cancer Research. 2020;18(2):300–310. doi: https://doi.org/10.1158/1541-7786.MCR-19-0588.CrossRefPubMed

65.

Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Annals of Oncology. 2017;28(4):741–747. doi: https://doi.org/10.1093/annonc/mdx004.CrossRefPubMedPubMedCentral

66.

Chu LC, Park S, Kawamoto S, Yuille AL, Hruban RH, Fishman EK. Pancreatic Cancer Imaging: A New Look at an Old Problem. Curr Probl Diagn Radiol. 2021;50(4):540–550. doi: https://doi.org/10.1067/j.cpradiol.2020.08.002.CrossRefPubMed

67.

LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436–444. doi: https://doi.org/10.1038/nature14539.CrossRefPubMed

68.

Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016;278(2):563–577. doi: https://doi.org/10.1148/radiol.2015151169.CrossRefPubMed

69.

Ahmed TM, Kawamoto S, Hruban RH, Fishman EK, Soyer P, Chu LC. A primer on artificial intelligence in pancreatic imaging. Diagnostic and Interventional Imaging. 2023; doi: https://doi.org/10.1016/j.diii.2023.03.002.CrossRefPubMed

70.

Chu LC, Park S, Kawamoto S, et al. Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue. AJR Am J Roentgenol. 2019;213(2):349–357. doi: https://doi.org/10.2214/AJR.18.20901.CrossRefPubMed

71.

Chen P-T, Chang D, Yen H, et al. Radiomic Features at CT Can Distinguish Pancreatic Cancer from Noncancerous Pancreas. Radiology: Imaging Cancer. 2021;3(4):e210010. https://doi.org/10.1148/rycan.2021210010.

72.

Chen P-T, Wu T, Wang P, et al. Pancreatic Cancer Detection on CT Scans with Deep Learning: A Nationwide Population-based Study. Radiology. 2022;220152. doi: https://doi.org/10.1148/radiol.220152.CrossRef

73.

Ozkan M, Cakiroglu M, Kocaman O, et al. Age-based computer-aided diagnosis approach for pancreatic cancer on endoscopic ultrasound images. Endosc Ultrasound. 2016;5(2):101–107. doi: https://doi.org/10.4103/2303-9027.180473.CrossRefPubMedPubMedCentral

74.

Cao K, Xia Y, Yao J, et al. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Nat Med. 2023;29(12):3033–3043. doi: https://doi.org/10.1038/s41591-023-02640-w.CrossRefPubMedPubMedCentral

75.

Korfiatis P, Suman G, Patnam NG, et al. Automated Artificial Intelligence Model Trained on a Large Data Set Can Detect Pancreas Cancer on Diagnostic Computed Tomography Scans As Well As Visually Occult Preinvasive Cancer on Prediagnostic Computed Tomography Scans. Gastroenterology. 2023;165(6):1533-1546.e4. doi: https://doi.org/10.1053/j.gastro.2023.08.034.CrossRefPubMed

76.

Qureshi TA, Gaddam S, Wachsman AM, et al. Predicting Pancreatic Ductal Adenocarcinoma Using Artificial Intelligence Analysis of Pre-diagnostic Computed Tomography Images. Cancer Biomark. 2022;33(2):211–217. doi: https://doi.org/10.3233/CBM-210273.CrossRefPubMedPubMedCentral

77.

Javed S, Qureshi TA, Gaddam S, et al. Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images. Front Oncol. 2022;12:1007990. doi: https://doi.org/10.3389/fonc.2022.1007990.CrossRefPubMedPubMedCentral

78.

Chen W, Zhou Y, Asadpour V, et al. Quantitative Radiomic Features From Computed Tomography Can Predict Pancreatic Cancer up to 36 Months Before Diagnosis. Clinical and Translational Gastroenterology. 2023;14(1):e00548. doi: https://doi.org/10.14309/ctg.0000000000000548.CrossRefPubMed

79.

Mukherjee S, Patra A, Khasawneh H, et al. Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diagnosis. Gastroenterology. 2022;163(5):1435-1446.e3. doi: https://doi.org/10.1053/j.gastro.2022.06.066.CrossRefPubMed

80.

Tobaly D, Santinha J, Sartoris R, et al. CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Cancers (Basel). 2020;12(11):3089. doi: https://doi.org/10.3390/cancers12113089.CrossRefPubMedPubMedCentral

81.

Cui S, Tang T, Su Q, et al. Radiomic nomogram based on MRI to predict grade of branching type intraductal papillary mucinous neoplasms of the pancreas: a multicenter study. Cancer Imaging. 2021;21(1):26. doi: https://doi.org/10.1186/s40644-021-00395-6.CrossRefPubMedPubMedCentral

82.

Cheng S, Shi H, Lu M, et al. Radiomics Analysis for Predicting Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Comparison of CT and MRI. Acad Radiol. 2022;29(3):367–375. doi: https://doi.org/10.1016/j.acra.2021.04.013.CrossRefPubMed

83.

Corral JE, Hussein S, Kandel P, Bolan CW, Bagci U, Wallace MB. Deep Learning to Classify Intraductal Papillary Mucinous Neoplasms Using Magnetic Resonance Imaging. Pancreas. 2019;48(6):805. doi: https://doi.org/10.1097/MPA.0000000000001327.CrossRefPubMed

84.

Kuwahara T, Hara K, Mizuno N, et al. Usefulness of Deep Learning Analysis for the Diagnosis of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clin Transl Gastroenterol. 2019;10(5):1–8. doi: https://doi.org/10.14309/ctg.0000000000000045.CrossRefPubMed

85.

Hernandez-Barco YG, Daye D, Fernandez-del Castillo CF, et al. IPMN-LEARN: A linear support vector machine learning model for predicting low-grade intraductal papillary mucinous neoplasms. Ann Hepatobiliary Pancreat Surg. 2023;27(2):195–200. doi: https://doi.org/10.14701/ahbps.22-107.CrossRefPubMedPubMedCentral

86.

Pereira SP, Oldfield L, Ney A, et al. Early detection of pancreatic cancer. The Lancet Gastroenterology & Hepatology. Elsevier; 2020;5(7):698–710. doi: https://doi.org/10.1016/S2468-1253(19)30416-9.CrossRef

87.

Finger A, Harris M, Nishimura E, Yoon H-C. Inadequate Clinical Indications in Computed Tomography Chest and Abdomen/Pelvis Scans. Perm J. 2018;22:18–017. doi: https://doi.org/10.7812/TPP/18-017.CrossRefPubMedPubMedCentral

88.

Vasen H, Ibrahim I, Ponce CG, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. J Clin Oncol. 2016;34(17):2010–2019. doi: https://doi.org/10.1200/JCO.2015.64.0730.CrossRefPubMed

89.

Overbeek KA, Levink IJM, Koopmann BDM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152–1160. doi: https://doi.org/10.1136/gutjnl-2020-323611.CrossRefPubMed

Titel: Early detection of pancreatic cancer in the era of precision medicine
verfasst von: Taha M. Ahmed
Satomi Kawamoto
Felipe Lopez-Ramirez
Mohammad Yasrab
Ralph H. Hruban
Elliot K. Fishman
Linda C. Chu
Publikationsdatum: 18.05.2024
Verlag: Springer US
Erschienen in: Abdominal Radiology
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-024-04358-w

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Early detection of pancreatic cancer in the era of precision medicine

Abstract

Graphical abstract

Neu im Fachgebiet Radiologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Update Radiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Radiologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Update Radiologie